The multivariable analysis, which considered factors such as age, gender, tumor location, BRAF mutation, MSI status, KRAS mutation, TGFβ2 mutation, and poor tumor differentiation, indicated that the combination of CEACAM5 methylation and sCEA levels independently affected disease prognosis (Table 5, p = 0.023) The results indicated that integration of sCEA and CEACAM5 promotor methylation presents a significant and informative approach for assessing disease prognosis. This evidence concerns the gene TGFB2 and neoplasm.